New Enterprise Associates, Inc. is a private equity and venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investing across various stages of business development, from seed funding to public offerings, with a strong emphasis on the technology and healthcare sectors. Its investment strategy encompasses a wide range of industries, including information technology, consumer internet, financial technology, software, healthcare services, life sciences, biopharmaceuticals, and energy technology. New Enterprise Associates actively engages with entrepreneurs to support the growth of their companies, making investments between $0.05 million and $20 million. The firm has a global investment focus, particularly in regions such as Asia, Brazil, and the United States.
Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.
Minerva Surgical
Post in 2022
Minerva Surgical Inc. is a medical technology company based in Redwood City, California, specializing in women's healthcare. Founded in 2008, the company develops, manufactures, and commercializes minimally invasive solutions aimed at addressing the unique uterine health needs of women. Its flagship product, The Minerva Endometrial Ablation System, provides a treatment option for abnormal uterine bleeding, a common issue among women. Minerva Surgical offers a range of alternatives to hysterectomy, designed to tackle the leading causes of abnormal uterine bleeding while preserving the uterus and minimizing the drawbacks associated with traditional treatment methods. The company's solutions are suitable for various medical settings, reflecting its commitment to improving women's health outcomes.
Pager
Series C in 2021
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
AllyAlign Health
Venture Round in 2021
AllyAlign Health operates as a care management company dedicated to supporting patients with chronic and complex medical conditions. Founded in 2013 and based in Glen Allen, Virginia, the company offers an active care management platform that facilitates real-time, collaborative care across various boundaries. This platform connects patients with care teams, providers, and community-based services, ensuring access to essential health information, care plans, and benefits necessary for informed decision-making. Users can easily view, share, create, and update information according to their roles and responsibilities, with mobile and web-based options enhancing accessibility for patients and their families. A central, HIPAA-compliant database consolidates information from multiple sources, including electronic health records and lab tests, while semantic data modeling provides meaningful clinical insights.
Strive Health
Series B in 2021
Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.
Tempus
Series G in 2020
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.
Pager
Series B in 2020
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Cardionomic
Venture Round in 2020
Cardionomic treats reduced cardiac output – ADHF’s root cause – by neuromodulating the terminal branches of the cardiac plexus to benignly increase contractility. Cardionomic’s acute, non-systemic therapy will improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Concurrently the therapy also achieves the associated decreases in plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), which are objective biomarkers of chronic heart failure.
ChromaCode
Series C in 2019
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.
Collective Health
Series E in 2019
Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Tempus
Series F in 2019
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.
Vesper Medical
Venture Round in 2019
Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.
Strive Health
Seed Round in 2019
Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.
Eargo
Series D in 2019
Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.
Sleep Reset
Series A in 2018
Sleep Reset is a personalized sleep program that utilizes a science-backed approach to address insomnia and improve sleep quality. Clinically proven to enhance total sleep time by an average of 85 minutes, the program effectively reduces the time taken to fall asleep and the frequency of nightly awakenings by nearly half. Participants work with a dedicated sleep coach who tailors the program to their specific needs, focusing on the underlying causes of sleep issues. This approach provides a sustainable solution for better sleep without the use of medications or melatonin. Developed in collaboration with sleep experts from esteemed institutions like Stanford and Yale, Sleep Reset has garnered recognition from various prominent publications and has received support from notable Silicon Valley investors. The program offers a comprehensive solution for individuals seeking to alleviate sleep anxiety and improve their overall sleep health.
Earlens
Series D in 2018
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.
Tempus
Series E in 2018
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.
Welltok
Series E in 2018
Welltok is a data-driven enterprise SaaS company based in Denver, Colorado, focused on enhancing consumer engagement in health and wellness. Founded in 2009, Welltok's leading consumer activation platform enables health plans, employers, providers, and public entities to connect individuals with personalized health improvement resources. The company's platform leverages a large consumer database and machine learning to facilitate targeted actions, making it easier for consumers to engage in activities that promote their health and wellbeing. Through its innovative solutions, Welltok aims to incentivize and support users in optimizing their health outcomes.
Tempus
Series D in 2018
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.
Collective Health
Series D in 2018
Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Pager
Series A in 2018
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Eargo
Series C in 2017
Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.
Tempus
Series C in 2017
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.
Earlens
Series C in 2017
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.
Sleep Reset
Seed Round in 2017
Sleep Reset is a personalized sleep program that utilizes a science-backed approach to address insomnia and improve sleep quality. Clinically proven to enhance total sleep time by an average of 85 minutes, the program effectively reduces the time taken to fall asleep and the frequency of nightly awakenings by nearly half. Participants work with a dedicated sleep coach who tailors the program to their specific needs, focusing on the underlying causes of sleep issues. This approach provides a sustainable solution for better sleep without the use of medications or melatonin. Developed in collaboration with sleep experts from esteemed institutions like Stanford and Yale, Sleep Reset has garnered recognition from various prominent publications and has received support from notable Silicon Valley investors. The program offers a comprehensive solution for individuals seeking to alleviate sleep anxiety and improve their overall sleep health.
ChromaCode
Series B in 2017
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.
Syllable
Seed Round in 2017
Syllable is a platform focused on enhancing communication between patients and healthcare providers through AI-driven text and voice interactions. It enables users to access important healthcare information, including details about primary care, specialty referrals, vaccinations, and general practice. By integrating AI agents and managing operations alongside third-party providers of large language models and AI services, Syllable aims to streamline the delivery of healthcare guidance and support outside traditional clinical environments.
Welltok
Series E in 2016
Welltok is a data-driven enterprise SaaS company based in Denver, Colorado, focused on enhancing consumer engagement in health and wellness. Founded in 2009, Welltok's leading consumer activation platform enables health plans, employers, providers, and public entities to connect individuals with personalized health improvement resources. The company's platform leverages a large consumer database and machine learning to facilitate targeted actions, making it easier for consumers to engage in activities that promote their health and wellbeing. Through its innovative solutions, Welltok aims to incentivize and support users in optimizing their health outcomes.
Pager
Venture Round in 2016
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Docent Health
Series A in 2016
Docent Health, based in Cambridge, Massachusetts, develops an enterprise consumer engagement platform aimed at enhancing patient care. The company focuses on helping health systems build and maintain lasting relationships with patients by integrating advanced consumer technology and hospitality-inspired service. Its platform combines digital and human interactions to provide personalized support through real-time text messaging, ensuring that patients receive empathetic and tailored experiences related to their clinical care. By leveraging best practices from various industries, Docent Health seeks to promote customer-centric care, ultimately increasing patient lifetime value and assisting healthcare organizations in expanding their market share.
Earlens
Series C in 2016
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.
Docent Health
Seed Round in 2016
Docent Health, based in Cambridge, Massachusetts, develops an enterprise consumer engagement platform aimed at enhancing patient care. The company focuses on helping health systems build and maintain lasting relationships with patients by integrating advanced consumer technology and hospitality-inspired service. Its platform combines digital and human interactions to provide personalized support through real-time text messaging, ensuring that patients receive empathetic and tailored experiences related to their clinical care. By leveraging best practices from various industries, Docent Health seeks to promote customer-centric care, ultimately increasing patient lifetime value and assisting healthcare organizations in expanding their market share.
DOTS
Series A in 2016
DOTS (Detection On The Spot) is changing the field of point of care detection with a revolutionary diagnostics platform with consumer and industrial applications. For the millions of consumers with food allergies, DOTS is creating a food allergen detection system to test food on the spot, provide more information for better decisions, and improve overall quality of life .
Eargo
Series B in 2015
Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.
Cardionomic
Series A in 2015
Cardionomic treats reduced cardiac output – ADHF’s root cause – by neuromodulating the terminal branches of the cardiac plexus to benignly increase contractility. Cardionomic’s acute, non-systemic therapy will improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Concurrently the therapy also achieves the associated decreases in plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), which are objective biomarkers of chronic heart failure.
23andMe
Series E in 2015
23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.
Pager
Series A in 2015
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Collective Health
Series B in 2015
Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Collective Health
Series B in 2015
Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Welltok
Series D in 2015
Welltok is a data-driven enterprise SaaS company based in Denver, Colorado, focused on enhancing consumer engagement in health and wellness. Founded in 2009, Welltok's leading consumer activation platform enables health plans, employers, providers, and public entities to connect individuals with personalized health improvement resources. The company's platform leverages a large consumer database and machine learning to facilitate targeted actions, making it easier for consumers to engage in activities that promote their health and wellbeing. Through its innovative solutions, Welltok aims to incentivize and support users in optimizing their health outcomes.
Dermira
Series C in 2014
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.
BetterDoctor
Series A in 2014
BetterDoctor helps validate and deliver accurate provider data to health plans, health systems, and hundreds of other companies via its API — from startups to publicly traded ones. This ultimately helps achieve the mission of helping consumers find the healthcare they need. Today, BetterDoctor's data platform and APIs power 9 health plans, 350 companies, 1,500 developers, helping millions of people find the right doctor each month. Health Plans BetterDoctor uses multi-modal outreach to drive providers to attest their information on BetterDoctor's online portal. API Partners BetterDoctor brings transparency to doctor data. Their real-time platform, master database and API services enable everyone to add doctor data to their systems, websites and applications. Today, BetterDoctor API and data tools power health insurance companies, healthcare startups and doctor search tools. https://betterdoctor.com/developers
Welltok
Series C in 2014
Welltok is a data-driven enterprise SaaS company based in Denver, Colorado, focused on enhancing consumer engagement in health and wellness. Founded in 2009, Welltok's leading consumer activation platform enables health plans, employers, providers, and public entities to connect individuals with personalized health improvement resources. The company's platform leverages a large consumer database and machine learning to facilitate targeted actions, making it easier for consumers to engage in activities that promote their health and wellbeing. Through its innovative solutions, Welltok aims to incentivize and support users in optimizing their health outcomes.
Collective Health
Series A in 2014
Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Dermira
Series B in 2013
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.
Omada
Series A in 2013
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
23andMe
Series D in 2012
23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.
Carticept Medical
Series C in 2012
Carticept Medical develops therapies to improve the quality of life of patients with osteoarthritis or cartilage damage. Carticept currently offers a cartilage implant product and distributes Sonosite ultrasound products.
Roka Bioscience
Series D in 2012
Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.
Omada
Seed Round in 2011
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
Goji Food Solutions
Series A in 2011
Goji Food Solutions provides RF solid-state cooking technology that enables healthier and simpler food preparation. It covers all the critical product development disciplines and helps its users plan their product roadmap, assist in application evaluation and hardware and software design, and license its growing IP portfolio for use in their products. Goji Food Solutions also provides various solutions, including the supply of RF modules and RF module integration services tailored to its users’ products. It was founded in 2009 and is based in Hamilton, Bermuda.
Dermira
Series A in 2011
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.
Roka Bioscience
Series C in 2011
Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.
23andMe
Series C in 2010
23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.
Predictive Biosciences
Series C in 2010
Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Carticept Medical
Series B in 2010
Carticept Medical develops therapies to improve the quality of life of patients with osteoarthritis or cartilage damage. Carticept currently offers a cartilage implant product and distributes Sonosite ultrasound products.
Minerva Surgical
Venture Round in 2010
Minerva Surgical Inc. is a medical technology company based in Redwood City, California, specializing in women's healthcare. Founded in 2008, the company develops, manufactures, and commercializes minimally invasive solutions aimed at addressing the unique uterine health needs of women. Its flagship product, The Minerva Endometrial Ablation System, provides a treatment option for abnormal uterine bleeding, a common issue among women. Minerva Surgical offers a range of alternatives to hysterectomy, designed to tackle the leading causes of abnormal uterine bleeding while preserving the uterus and minimizing the drawbacks associated with traditional treatment methods. The company's solutions are suitable for various medical settings, reflecting its commitment to improving women's health outcomes.
CITIC Pharmaceutical
Series D in 2009
CITIC Pharmaceutical Co., Ltd. (中信医药) is a pharmaceutical service provider that supplies medicine and related consumables to hospitals. It is a large pharmaceutical operation enterprise integrating medicines supply to hospitals, cross-regional commercial distribution, vaccine sale, medical instruments and consumables sale, and medicine retailing service. In recent years, it has become a pharmaceutical service provider in the supply chain with multiple customized integration service. CITIC Pharmaceutical, which is a subsidiary of CITIC Group, was transformed to a joint venture in 2007. It is invested by China Health System whose holding company is Bioveda China fund and CITIC Investment Holdings Ltd.
23andMe
Series B in 2009
23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.
Predictive Biosciences
Series B in 2008
Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
CITIC Pharmaceutical
Series C in 2008
CITIC Pharmaceutical Co., Ltd. (中信医药) is a pharmaceutical service provider that supplies medicine and related consumables to hospitals. It is a large pharmaceutical operation enterprise integrating medicines supply to hospitals, cross-regional commercial distribution, vaccine sale, medical instruments and consumables sale, and medicine retailing service. In recent years, it has become a pharmaceutical service provider in the supply chain with multiple customized integration service. CITIC Pharmaceutical, which is a subsidiary of CITIC Group, was transformed to a joint venture in 2007. It is invested by China Health System whose holding company is Bioveda China fund and CITIC Investment Holdings Ltd.
23andMe
Series A in 2007
23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.
Bariatric Partners
Series B in 2006
Bariatric Partners, based in Charlotte, North Carolina, focuses on developing a network of outpatient surgical facilities specifically designed to cater to the needs of individuals suffering from severe obesity. The company collaborates closely with physician partners who contribute to the design and layout of these facilities, ensuring that the selection of equipment and the hiring of essential staff meet the highest standards. Additionally, Bariatric Partners is involved in creating and implementing comprehensive patient support services, enhancing the overall care and recovery experience for its patients.
Appriva Medical
Venture Round in 2000
Appriva Medical is engaged in the design and manufacture of medical equipment for preventing cardioembolic stroke in patients with atrial fibrillation.
WebMD
Venture Round in 1996
WebMD is a prominent provider of health information and services aimed at both consumers and healthcare professionals. The company offers a wide range of resources, including online health-focused publications and decision-support applications, that empower users to manage their health actively. WebMD delivers objective healthcare and lifestyle information through various platforms, enabling individuals to access critical data about conditions such as HIV, diabetes, depression, and cancer. It also serves healthcare professionals by providing access to clinical reference sources, the latest treatment options, and opportunities for continuing medical education. Additionally, WebMD collaborates with employers and health plans to offer personalized health information and decision support tools for employees and plan members, fostering informed choices regarding benefits, providers, and treatment options.
Diatide
Venture Round in 1993
Diatide is engaged in the imaging marketplace, engaged in peptide engineering, molecular biology, and radiolabeling chemistry to develop disease-specific diagnostic and therapeutic agents.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.